SEARCH

SEARCH BY CITATION

References

  • 1
    Howden CW, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 2001; 96: 170410.
    Direct Link:
  • 2
    Johnsson F, Hatlebakk JG, Klintenberg A-C, Roman J. The symptom relieving effect of esomeprazole 40 mg daily in patients with heartburn. Gastroenterology 2001; 120: A437(Abstract).
  • 3
    Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 65665.
    Direct Link:
  • 4
    Kahrilas P, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 124958.
  • 5
    Feldman M, Harford WV, Fisher RS, et al. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K+-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. Am J Gastroenterol 1993; 88: 12127.
  • 6
    Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 1995; 9: 2531.
  • 7
    Robinson M, Campbell DR, Sontag S, Sabesin SM. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995; 40: 5907.
  • 8
    El-Omar E, Banerjee S, Wirz A, Penman I, Ardill JE, McColl KE. Marked rebound acid hypersecretion after treatment with ranitidine. Am J Gastroenterol 1996; 91: 3559.
  • 9
    Smith AD, Gillen D, Cochran KM, El-Omar E, McColl KE. Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers. Am J Gastroenterol 1999; 94: 120913.
  • 10
    Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 23947.
  • 11
    Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol 2001; 15: 48795.
  • 12
    Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol 2001; 33: 2069.
  • 13
    Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 57583.
    Direct Link:
  • 14
    Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 32735.
  • 15
    Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 48796.
  • 16
    Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 92735.
  • 17
    Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 2734.
    Direct Link:
  • 18
    Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of on-demand therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 34754.
  • 19
    Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol 2001; 116: 71620.
  • 20
    Cats A, Schenk BE, Bloemena E, et al. Parietal cell protusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 2000; 31: 68490.
  • 21
    Kuipers EJ, Meuwissen SG. The efficacy and safety of long-term omeprazole treatment for gastroesophageal reflux disease. Gastroenterology 2000; 118: 7958.
  • 22
    Armstrong D. Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease. The Lancet 2000; 356: 6102.
  • 23
    Sanduleanu S, Jonkers D, De Bruïne A, Hameeteman W, Stockbrügger RW. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther 2001; 15: 116375.
  • 24
    Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrügger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 2001; 15: 37988.
  • 25
    Theisen J, Nebra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000; 4: 504.
  • 26
    Mowat C, Williams C, Gillen D, et al. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology 2000; 119: 33947.
  • 27
    Nwokolo CU, Loft DE, Holder R, Langman MJ. Increased incidence of bacterial diarrhoea in patients taking gastric acid antisecretory drugs. Eur J Gastroenterol Hepatol 1994; 6: 6979.
  • 28
    Larner AJ, Hamilton MI. Review article: infective complications of therapeutic gastric acid inhibition. Aliment Pharmacol Ther 1994; 8: 57984.
  • 29
    Lundell L, Miettinen P, Myrvold et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192: 17281.
  • 30
    Sagar M, Janczewska I, Ljungdahl Å, Bertilsson L, Seensalu R. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther 1999; 13: 4538.
  • 31
    Joshi SN, Gardner JD. Gastrin and colon cancer: a unifying hypothesis. Dig Dis 1996; 14: 33444.
  • 32
    Dockray GJ. Gastrin growth, and colon neoplasia. Gut 2000; 47: 7478.
  • 33
    Johnsson L, Adlouni W, Johnsson F, Joelsson B. Timing of reflux symptoms and esophageal acid exposure. Gullet 1992; 2: 5862.
  • 34
    Khoury RM, Katz PO, Hammod R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999; 13: 6758.
  • 35
    Fackler WK, Ours TM, Vaezi MF, Richter JE. H2Ras do not provide sustained suppression of nocturnal acid breakthrough. Gastroenterology 2001; 120 (Suppl. 1): A33.
  • 36
    Hameeteman W, Tytgat GN, Houthoff HJ, Van Den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 124956.
  • 37
    Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma in Barrett's oesophagus. Dig Dis Sci 1989; 34: 13369.
  • 38
    Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988; 75: 7603.
  • 39
    Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32: 14416.
  • 40
    Williamson WA, Ellis FH Jr, Gibb SP et al. Barrett's oesophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991; 151: 22126.
  • 41
    Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988; 83: 2914.
  • 42
    Spechler SJ, Robbins AH, Rubins HB et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984; 87: 92733.
  • 43
    Van Der Burgh A, Dees J, Hop WC, Van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 58.
  • 44
    Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 2125.
  • 45
    O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94: 203742.
  • 46
    Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 8579.
  • 47
    Lafullarde T, Watson DI, Jamieson GG et al. Laparoscopic Nissen fundoplication. Arch Surg 2001; 136: 1804.
  • 48
    Bammer T, Hinder RA, Klaus A, Klinger PJ. Five-to-eight year outcome of the first laparoscopic Nissen fundoplications. J Gastrointest Surg 2001; 5: 438.
  • 49
    Klinkenberg-Knol EC, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 6619.